Healthcare is moving toward a more personalised model, where treatments are increasingly tailored to the biology of individual patients rather than designed only for broad populations.
Advances in genetics, data analysis and diagnostics are allowing doctors to identify which therapies may work best for specific people. This approach, often called precision medicine, is already influencing areas such as cancer care and rare disease treatment.
Researchers and institutions including the National Institutes of Health are investing heavily in this field, seeing it as a major shift in medical practice.
The benefits could be significant. More targeted treatments may improve outcomes, reduce side effects and avoid unnecessary interventions.
However, access remains a central challenge. Genetic testing, advanced diagnostics and specialised therapies can be expensive and are not equally available across countries or income groups.
There are also concerns about privacy, as personalised medicine often depends on large amounts of sensitive health data.
Experts say the long-term success of personalised healthcare will depend not only on scientific progress, but on whether systems can make these advances widely accessible.
The future of medicine may be more precise — but it must also become more equitable.
